Noelia Gómez-Aguirre1,2, Daniel Fuertes-Ruiz3, Borja Gracia-Tello4, Carolina Clemente-Sarasa3, Ester Artajona-Rodrigo5, José-Luis Cabrerizo-García2,6, Begoña de Escalante-Yangüela2,4, María-Carmen Bueno-Castel5, José Velilla-Marco5, Jesús Díez-Manglano7,8. 1. Internal Medicine Department, Hospital Ernest Lluch, Calatayud, Spain. 2. Research Group on Comorbidity and Polyphatology in Aragón, Aragón Health Sciences Institute, Avda San Juan Bosco 13 (CIBA), 50009, Zaragoza, Spain. 3. Internal Medicine Department, Hospital Royo Vilanova, Zaragoza, Spain. 4. Internal Medicine Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. 5. Internal Medicine Department, Hospital Miguel Servet, Zaragoza, Spain. 6. Internal Medicine Department, Hospital General de la Defensa, Zaragoza, Spain. 7. Research Group on Comorbidity and Polyphatology in Aragón, Aragón Health Sciences Institute, Avda San Juan Bosco 13 (CIBA), 50009, Zaragoza, Spain. jdiez@aragon.es. 8. Internal Medicine Department, Hospital Miguel Servet, Zaragoza, Spain. jdiez@aragon.es.
Abstract
OBJECTIVE: To externally validate the PALIAR index for patients with advanced, nononcologic chronic diseases. METHODS: We performed a prospective, multicenter cohort study that included patients with advanced, nononcologic chronic diseases hospitalized in internal medicine departments and treated consecutively by the researchers between July 1st and December 31st, 2014. Data were collected from each patient on age, sex, advanced disease, Charlson index, comorbidities, Barthel index, terminal illness symptoms, need for caregiver, hospitalization in the past 3 and 12 months and number of drugs. We calculated the PALIAR index and conducted a 6-month follow-up. To analyze the association between the variables and mortality, we constructed several multivariate logistic regression models. RESULTS: The study included 295 patients with a mean age of 82.7 (8.6) years, 148 (50.2%) of whom were women. Mortality at 6 months was associated with the albumin level (OR 0.52, 95% CI 0.30-0.85, p = 0.011), and the terminal illness (OR 2.75, 95% CI 1.55-4.89, p = 0.001). The PALIAR index showed good discrimination for predicting mortality (statistical C, 0.728, 95% CI 0.670-0.787). A reduced version of the PALIAR index showed similar mortality discriminatory power. CONCLUSIONS: The PALIAR index is a reliable tool for predicting mortality in patients with advanced, nononcologic chronic diseases.
OBJECTIVE: To externally validate the PALIAR index for patients with advanced, nononcologic chronic diseases. METHODS: We performed a prospective, multicenter cohort study that included patients with advanced, nononcologic chronic diseases hospitalized in internal medicine departments and treated consecutively by the researchers between July 1st and December 31st, 2014. Data were collected from each patient on age, sex, advanced disease, Charlson index, comorbidities, Barthel index, terminal illness symptoms, need for caregiver, hospitalization in the past 3 and 12 months and number of drugs. We calculated the PALIAR index and conducted a 6-month follow-up. To analyze the association between the variables and mortality, we constructed several multivariate logistic regression models. RESULTS: The study included 295 patients with a mean age of 82.7 (8.6) years, 148 (50.2%) of whom were women. Mortality at 6 months was associated with the albumin level (OR 0.52, 95% CI 0.30-0.85, p = 0.011), and the terminal illness (OR 2.75, 95% CI 1.55-4.89, p = 0.001). The PALIAR index showed good discrimination for predicting mortality (statistical C, 0.728, 95% CI 0.670-0.787). A reduced version of the PALIAR index showed similar mortality discriminatory power. CONCLUSIONS: The PALIAR index is a reliable tool for predicting mortality in patients with advanced, nononcologic chronic diseases.
Authors: Pere Almagro; Ana Ponce; Shakeel Komal; Maria de la Asunción Villaverde; Cristina Castrillo; Gemma Grau; Lluis Simon; Alex de la Sierra Journal: PLoS One Date: 2020-01-28 Impact factor: 3.240